Carol C. Kenney

Calgary, AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Justification of deferral of consent in the ACT-GLOBAL adaptive platform trial in stroke.

Justification of deferral of consent in the ACT-GLOBAL adaptive platform trial in stroke.

Journal: Journal of clinical epidemiology

Published: November 14, 2025

COSMOS: Interrater and Intrarater Reliability Study of a Novel Outcome Measure.

COSMOS: Interrater and Intrarater Reliability Study of a Novel Outcome Measure.

Journal: Stroke

Published: June 23, 2025

Patient and Caregiver Perspectives on the Design and Execution of ACT-GLOBAL, a Stroke Adaptive Platform Trial: A Focus Group Study.

Patient and Caregiver Perspectives on the Design and Execution of ACT-GLOBAL, a Stroke Adaptive Platform Trial: A Focus Group Study.

Journal: Cerebrovascular diseases (Basel, Switzerland)

Published: December 23, 2024

Consent-Related Outcomes in the Alteplase Compared to Tenecteplase Trial.

Consent-Related Outcomes in the Alteplase Compared to Tenecteplase Trial.

Journal: Neurology

Published: November 07, 2024

A Randomized Controlled Trial of Tenecteplase Versus Standard of Care for Minor Ischemic Stroke with Proven Occlusion (TEMPO-2): Rational and design of a multicenter, randomized open-label clinical trial.

A Randomized Controlled Trial of Tenecteplase Versus Standard of Care for Minor Ischemic Stroke with Proven Occlusion (TEMPO-2): Rational and design of a multicenter, randomized open-label clinical trial.

Journal: International journal of stroke : official journal of the International Stroke Society

Published: April 27, 2024

Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.

Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.

Journal: Lancet (London, England)

Published: April 18, 2024

Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial.

Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial.

Journal: Stroke

Published: January 26, 2024

Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.

Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.

Journal: Lancet (London, England)

Published: May 23, 2022

Ethical Justification for Deferral of Consent in the AcT Trial for Acute Ischemic Stroke.

Ethical Justification for Deferral of Consent in the AcT Trial for Acute Ischemic Stroke.

Journal: Stroke

Published: May 23, 2022

AcT Trial: Protocol for a Pragmatic Registry-Linked Randomized Clinical Trial.

AcT Trial: Protocol for a Pragmatic Registry-Linked Randomized Clinical Trial.

Journal: Stroke (Hoboken, N.J.)

Published: March 30, 2022

Understanding Physician and Patient Preferences for Thrombolysis in Ischemic Stroke Eligible for Endovascular Thrombectomy.

Understanding Physician and Patient Preferences for Thrombolysis in Ischemic Stroke Eligible for Endovascular Thrombectomy.

Journal: Stroke (Hoboken, N.J.)

Published: October 03, 2021

Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.

Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.

Journal: Stroke

Published: February 14, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026